Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.41 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360466 | 0.89 | HSD11B1 (0.49) | HSD11B1HSD11B2ALDH1A1LMNAHTT | |
| SCHEMBL328751 | 0.73 | HSD11B1 (0.46) | HSD11B1HSD11B2LMNAHTTSMN1; SMN2 | |
| SCHEMBL328846 | 0.71 | HSD11B1 (0.85) | HSD11B1HSD11B2 | |
| SCHEMBL328952 | 0.68 | HSD11B1 (0.48) | HSD11B1HSD11B2ALDH1A1 | |
| SCHEMBL328803 | 0.65 | HSD11B1 (0.63) | HSD11B1HSD11B2LMNAHTTSMN1; SMN2 | |
| SCHEMBL328843 | 0.65 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL11222426 | 0.65 | SMN1; SMN2 (0.42) | HSD11B1HSD11B2ALDH1A1LMNAHTT | |
| SCHEMBL329103 | 0.63 | HSD11B1 (0.42) | HSD11B1HSD11B2ALDH1A1LMNAHTT | |
| SCHEMBL19928066 | 0.62 | HSD11B1 (0.38) | HSD11B1HSD11B2ALDH1A1LMNA | |
| SCHEMBL17893906 | 0.59 | BRD4 (0.36) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007719-B1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2407452-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | Abbott Laboratories (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7737137-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2007719-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | US | disclosed |
| US-7435833-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2007118185-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885HSD11B2 2/4885ALDH1A1 132/4885 |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885ALDH1A1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.